ReViral Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 22


  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $525M

ReViral General Information


Developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drug is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe diseases including neonates, enabling patients to be treated who are infected with the respiratory syncopal virus (RSV) by developing novel compounds.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Corporate Office
  • Stevenage Bioscience Catalyst
  • Gunnels Wood Road, Hertfordshire
  • Stevenage SG1 2FX
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ReViral Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 06-Apr-2022 $525M 00000 00000 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series C) 25-Aug-2020 000.00 00000 00000 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series B) 01-Aug-2018 000.00 000.00 00000 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 08-Sep-2015 000.00 000.00 000.00 Completed Pre-Clinical Trials
2. Angel (individual) 03-Dec-2014 $1.57M $1.83M Completed Pre-Clinical Trials
1. Angel (individual) 26-Feb-2013 $252K $252K 00000 Completed Startup
To view ReViral’s complete valuation and funding history, request access »

ReViral Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000 00.000000 00000.00 00000.00 00 00000.00 00.000
Series B 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Series A 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Series A 0,000 00.000000 0000.0 0000.0 00 0000.0 0.000
Ordinary 4,355 $0.013069 $6.53 $6.53 $6.53 2.17%
Ordinary 12,400 $0.013069
To view ReViral’s complete cap table history, request access »

ReViral Comparisons

HQ Location
Total Raised
Post Valuation
Developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-cla
Drug Discovery
Stevenage, United Kingdom
22 As of 2022
00000 0000-00-00
000000&0 00000


d minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
London, United Kingdom
000 As of 0000
000.00 0000-00-00
000000&0 00000


rehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excep
0000 000000000
Tucson, AZ
0 As of 0000
00000000000 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ReViral Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
hVIVO Formerly VC-backed London, United Kingdom 000 00000 000000&0 00000
Aqualung Therapeutics Venture Capital-Backed Tucson, AZ 0 00.00 00000000000 00.00
Enterprise Therapeutics Venture Capital-Backed Brighton, United Kingdom 00 0000 00000000000 0000
Moerae Matrix Formerly VC-backed Morristown, NJ 0 000.00 00000000000 000.00
Windtree Therapeutics Corporate Backed or Acquired Warrington, PA 00 00000 00000000 00000
You’re viewing 5 of 20 competitors. Get the full list »

ReViral Patents

ReViral Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202102602-D0 Pharmaceutical compounds Inactive 24-Feb-2021 0000000000
GB-202010409-D0 Pharmaceutical compounds Inactive 07-Jul-2020 0000000000
GB-202010408-D0 Pharmaceutical compounds Inactive 07-Jul-2020 000000000
US-20230270751-A1 Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection Pending 07-Jul-2020 00000000000
US-20230365585-A1 Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection Pending 07-Jul-2020 C07D498/04
To view ReViral’s complete patent history, request access »

ReViral Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ReViral Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Andera Partners PE/Buyout Minority 000 0000 000000 0
Brace Pharma Capital Corporate Venture Capital Minority 000 0000 000000 0
Charoen Pokphand Group VC-Backed Company Minority 000 0000 000000 0
China Resources Capital Management Corporate Venture Capital Minority 000 0000 000000 0
Green Sands Equity Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

ReViral FAQs

  • When was ReViral founded?

    ReViral was founded in 2011.

  • Who is the founder of ReViral?

    Stuart Cockerill Ph.D and Neil Mathews Ph.D are the founders of ReViral.

  • Where is ReViral headquartered?

    ReViral is headquartered in Stevenage, United Kingdom.

  • What is the size of ReViral?

    ReViral has 22 total employees.

  • What industry is ReViral in?

    ReViral’s primary industry is Drug Discovery.

  • Is ReViral a private or public company?

    ReViral is a Private company.

  • What is the current valuation of ReViral?

    The current valuation of ReViral is 00000.

  • What is ReViral’s current revenue?

    The current revenue for ReViral is 00000.

  • How much funding has ReViral raised over time?

    ReViral has raised $126M.

  • Who are ReViral’s investors?

    Andera Partners, Brace Pharma Capital, Charoen Pokphand Group, China Resources Capital Management, and Green Sands Equity are 5 of 10 investors who have invested in ReViral.

  • Who are ReViral’s competitors?

    hVIVO, Aqualung Therapeutics, Enterprise Therapeutics, Moerae Matrix, and Windtree Therapeutics are some of the 20 competitors of ReViral.

  • When was ReViral acquired?

    ReViral was acquired on 06-Apr-2022.

  • Who acquired ReViral?

    ReViral was acquired by Pfizer (Pharmaceuticals).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »